AbbVie Inc. buy Piper Jaffray Companies
Summary
This prediction ended on 29.07.24 with a price of €170.60. The BUY prediction by Piper_Jaffray_Compan finished with a performance of 24.07%. Piper_Jaffray_Compan has a follow-up prediction for AbbVie Inc. where he still thinks AbbVie Inc. is a Buy. Dividends of €4.28 are taken into consideration when calculating the performance. Piper_Jaffray_Compan has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
AbbVie Inc. | 1.444% | 1.444% | 26.054% |
iShares Core DAX® | -1.114% | 3.430% | 25.966% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% |
Comments by Piper_Jaffray_Compan for this prediction
In the thread AbbVie Inc. diskutieren
In the thread Trading AbbVie Inc.